Atavistik Bio’s Post

🎙 Up next, Ms. Lydia Bernard-Jones from Sierra Leone. RSVP via this link: https://lnkd.in/dW9u6WUU to hear Lydia speak. 📰Fact checker! Biotech activity in Africa is nascent, but international pharma is tapping into the continent's genetic diversity for clinical trials and therapy development. 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐨𝐧 𝟏𝟔𝐭𝐡 𝐉𝐮𝐥𝐲 𝟐𝟎𝟐𝟒 𝐚𝐭 𝟖 𝐏𝐌 𝐄𝐀𝐓 | 𝟔 𝐏𝐌 𝐖𝐀𝐓 | 𝟓 𝐏𝐌 𝐆𝐌𝐓

Discover how leading life science companies are overcoming challenges and raising significant funds to drive innovation! This panel will feature industry leaders discussing their unique scientific pursuits, products, and the financial and regulatory hurdles in today’s competitive life sciences market. 🎤 Speakers include: Jang-Ho Cha, Latus Therapeutics Josh Muntner, CFO, Imvax, Inc. Moderated by John Pennett, EisnerAmper Advisory Services. Join us for this insightful session at the Philly Builds Bio+ Third Annual Symposium! 🔗 Register today: phillybuildsbio.org #PhillyBuildsBio #LifeSciences #InvestmentOpportunities #FinancingSuccess #BiotechInnovation

Can behavioural science-informed thinking help us increase the adoption of patient and public involvement in research? In the latest publication of DIA’s Global Forum, Liz Clark, visiting lecturer at Centre for Pharmaceutical Medicine Research, King's College London and Amy Rogers, University of Dundee, reflect on reasons why patient and public involvement (PPI) is not yet embedded into research, and how acknowledging the frictions of involvement in research can help move us forward and increase adoption of PPI. Many thanks Liz & Amy for this thought-provoking perspective. 🚨 Call to action: • What frictions have you experienced in PPI? • What has stopped you from adopting PPI as standard? • What are your concerns? • What can we do to help? Share your thoughts in the comments ⬇️

I am participating LSN Webinar to share my two cents on growing interest of JP startups/biotechs on Go-to-market strategy abroad and what improvement is needed to achieve it.

#News: Evotec announced further progress of the company’s strategic partnership with Bristol Myers Squibb relating to building a #molecularglue-based pipeline, triggering a $75 million performance-based and program-based milestone payment to #Evotec.   Initiated in 2018, the partnership combines Evotec’s high-performance #multiomics #screening and #analytics capabilities with #BristolMyersSquibb’s library of #cereblon #E3 #ligasemodulators (CELMoDs). Expanded in 2022, the partnership continues to identify #novelmoleculargluedegraders, targeting high-value targets in the field of #oncology and beyond.    Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “Bristol Myers Squibb is leading the industry in the field of molecular glue degraders, which is clearly one of the most exciting emerging therapeutic modalities. Through our highly systematic and industrialized PanOmics-based approach the pipeline of molecular degraders addressing high value targets keeps growing and maturing. The breadth and the depth of the pipeline is designed to deliver multiple first-in-class products into the market. We are well on track to deliver on our plans.” 🕮 Read more from Contract Pharma 👉🏼 https://lnkd.in/eWgevNNg

Selecting the right target is key for successful drug discovery! On February 12th, 2024 SciLifeLab Drug Discovery & Development at SciLifeLab is co-organizing a webinar with Cancer Research Horizons and Karolinska Institutet where you will learn more about what to consider. The webinar is free and open to everyone - please join! #drugdiscovery #drugdevelopment

#SwissBiotechDay #AkcesoAdvisors #AndrásIncze Join us at the Swiss Biotech Day next Monday and Tuesday, where our Founder & CEO, Andras Incze, will be serving as a jury member on two pitching sessions! 🎉   The Swiss Biotech Day, hosted by the Swiss Biotech Association, is one of Europe's premier biotechnology conferences, bringing together 2,000 professionals from the global life sciences community.   We are very much looking forward to explore how we at Akceso Advisors could help participating biotechs make sure they maximize the value of their asset. This, by helping them reaching target price for the target patient population, thus maximizing net revenue in an ever-more-challenging pharma landscape.   See you there! ✍ Find the registration link in the first comment.  

Congratulations to South Rampart Pharma, Inc. on publishing their research in the Scientific Reports journal! Their paper, titled "Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region," showcases the groundbreaking work on their lead asset, SRP-001, which has received FDA Fast Track Designation. This publication highlights the unique mechanisms of action and transcriptomic profiles that contribute to SRP-001's promising therapeutic potential as a non-hepatotoxic analgesic as well as data from their Phase 1 clinical trial. Read more about this paper: https://bit.ly/3QNhwrw

For those interested, I will be giving a webinar on our cells and technology this Wednesday. It is free, and hosted by our friends at REPROCELL And, it is available twice! First at EU time and later at noon EST. If you want to know why and how HD-DoE stands out compared to hypothesis driven research, or direct programming, this will be explained. #trailbio #hddoe #trailhead #stemcells #ipsc #celltherapy #directeddifferentiation #biology #futuremedicine #drugdiscovery #hts #regenerativemedicine Please follow us at Trailhead Biosystems

In Edison Group’s last BB Biotech (BION) review note, published in May 2024, they noted that the biotech sector was eagerly awaiting some key milestones, the most important being Alnylam Pharmaceuticals’ late-stage clinical trial of vutrisiran for patients with ATTR cardiomyopathy, a deadly heart disease. Alnylam, which comprised 4.3% of BION’s portfolio at end March 2024, released very positive, statistically significant, Phase III trial results this week. Assuming regulatory clearance, Alnylam expects that vutrisiran has the potential to become the new standard of care for the treatment of this disease, driving substantial future growth for the company. These results may have favourable implications for sentiment across the broader global biotech sector, and for Ionis Pharmaceuticals, BION’s largest portfolio position, which is also developing gene-silencing technology.   #biotech #Markets #Investment  https://lnkd.in/esKu7Evt